Mia's Feed
Medical News & Research

Exploring Low-Dose Naltrexone as a Potential Treatment for Long COVID

Exploring Low-Dose Naltrexone as a Potential Treatment for Long COVID

Share this article

Research from Griffith University suggests that low-dose naltrexone, a drug used for opioid addiction, may be an effective treatment for Long COVID by restoring cellular function and improving symptoms.

2 min read

Recent research from Griffith University has indicated that low-dose naltrexone (LDN), a medication traditionally used for opioid addiction, may offer new hope in the fight against Long COVID. A study published in Frontiers in Molecular Biosciences demonstrated that LDN successfully restored cellular function in human cells affected by Long COVID.

Long COVID, affecting over 77 million people worldwide, causes persistent symptoms such as fatigue, neurological issues, and immune dysfunction long after the initial infection resolves. The study’s lead researcher, Professor Sonya Marshall-Gradisnik of Griffith’s National Center for Neuroimmunology and Emerging Diseases (NCNED), emphasized the urgency for effective treatments, and highlighted that LDN is a safe, repurposed drug.

The team’s prior investigations revealed that TRPM3 ion channels, which facilitate calcium transport into cells and are vital for cellular signaling, are faulty in Long COVID patients. Ph.D. candidate Etianne Sasso explained that these defective ion channels can be likened to malfunctioning doors in a house, preventing essential calcium entry. This impairment hampers various bodily functions, including immune responses and neurological activity.

The study demonstrated that low-dose naltrexone effectively fixes these dysfunctional 'doors,' enabling proper opening and closing of ion channels. Since these channels influence key processes such as immune response and pain regulation, restoring their function could significantly alleviate Long COVID symptoms. Currently, NCNED is conducting clinical trials to evaluate LDN’s effectiveness in improving symptoms, disability, and quality of life among Long COVID patients.

This promising discovery offers a new avenue for treating a condition that has been challenging to manage and highlights the potential of drug repurposing in medical research.

Source: https://medicalxpress.com/news/2025-05-drug-typically-opioid-addiction-covid.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Innovative Gene Therapy Strategies Target Advanced Inherited Retinal Degenerations

New gene therapy promoters show promise for treating advanced stages of inherited retinal degenerations, potentially restoring vision even after significant retinal damage.

Advances and Challenges in Duchenne Muscular Dystrophy Gene Therapy

Exploring current developments in Duchenne muscular dystrophy gene therapy, including FDA approval, efficacy challenges, safety concerns, and high costs, offering hope amid ongoing research efforts.